Commercial Readiness:
Two Sides of the Exit Coin

In today’s tighter funding environment, a high valuation is no longer guaranteed by historical revenue alone. Investors are looking deeper into the quality, predictability, and scalability of your commercial engine. To bridge the gap between internal operations and external investment standards, Zymewire is joined by the specialized expertise of Bourne Partners and ILIKOS Consulting Group.

Join us for a conversation that explores the intersection of mid-market investment banking and frontline commercial strategy. We will unpack the specific financial benchmarks and operational frameworks that transform a Life Sciences service provider from a functional business into a premium, de-risked acquisition target.

Can’t join us live on March 4th? Register anyway and we’ll send the full session recording along with a summary of the key strategic takeaways.

Reserve my Seat

Ryan Silvester

Investment Banker, Bourne Partners

Ryan is a specialist in global M&A and financing advisory with a dedicated focus on Pharma Services and Healthcare Technology. Representing Bourne Partners, a firm with a 25-year legacy at the forefront of healthcare finance, Ryan helps Life Sciences businesses navigate complex sell-side and buy-side transactions. His expertise lies in identifying the specific value drivers that bridge the gap between a company's current operations and its ultimate investment potential within the global healthcare ecosystem.

Elias Sayias

Founder, ILIKOS Consulting Group

Elias is a clinical research veteran with over 15 years of experience bridging the gap between clinical operations and global commercial strategy. As the founder of ILIKOS Consulting Group, he has secured over $250M in new revenue for CROs and MedTech organizations by implementing tactical, market-driven go-to-market solutions. He is dedicated to helping service providers move beyond traditional sales to build sophisticated, high-growth commercial engines.

Ali Babar

Director of Sales, Zymewire

With a foundation in multidisciplinary scientific research spanning psychiatry and chemical engineering, Ali brings a data-driven, analytical lens to the commercial landscape. He has spent years advising commercial teams within the biotech and pharma services sectors, helping them move beyond traditional prospecting to build sophisticated, high-performance sales engines. At Zymewire, he focuses on equipping organizations with the intelligence and frameworks necessary to identify market signals and drive sustainable, scalable growth.

Who Should Join the Conversation

🏢

Service Providers

Tailored for small-to-mid CROs, CDMOs, clinical sites, and eClinical platforms looking to professionalize their commercial engine.

👥

Commercial Leaders

Ideal for C-Suite executives, VPs, and Directors of BD, as well as high-growth managers eager to master sophisticated sales methodologies.

📈

Future Focused

Critical for private organizations evaluating a future exit, acquisition, or capital raise who need to build immediate commercial credibility.

"If your business development has felt reactive, relying on conferences and existing relationships, this discussion will provide the framework needed to build a proactive, scalable, and exit or acquisition-ready organization."

The Stakes: Why Commercial Maturity Matters

Analyze why current market shifts demand a transition toward de-risked revenue and TAM credibility.

Building the Exit-Ready Commercial Engine

Define the pillars of an "exit-ready" commercial organization, focusing on tactical BD methodology and building a diverse, winnable project mix.

Securing the Premium: Investor Metrics

Master the KPIs that drive multiples: from Backlog and Net Revenue Retention to building a credible TAM → SAM → SOM roadmap for diligence.

Commercial Readiness: Two Sides of the Exit Coin